Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunogen Inc (NQ: IMGN ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Immunogen Inc < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 01, 2022 From ImmunoGen, Inc. Via Business Wire Short Volatility Alert: ImmunoGen, Inc. August 31, 2022 On Tuesday, shares of ImmunoGen, Inc. (NASDAQ: IMGN) experienced volatile short activity. After the activity, the stock price went down -0.86% to $5.75. The overall sentiment for IMGN has been... Via Benzinga ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm August 31, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 01, 2022 From ImmunoGen, Inc. Via Business Wire Recap: Immunogen Q2 Earnings July 29, 2022 Immunogen (NASDAQ:IMGN) reported its Q2 earnings results on Friday, July 29, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Via Benzinga Immunogen: Q1 Earnings Insights May 06, 2022 Immunogen (NASDAQ:IMGN) reported its Q1 earnings results on Friday, May 6, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session July 29, 2022 Via Benzinga Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update July 29, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results July 29, 2022 From ImmunoGen, Inc. Via Business Wire Earnings Preview For Immunogen July 28, 2022 Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-07-29. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will... Via Benzinga Earnings Scheduled For July 29, 2022 July 29, 2022 Companies Reporting Before The Bell • Capital Product Partners (NASDAQ:CPLP) is expected to report quarterly earnings at $1.13 per share on revenue of $72.73 million. Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session July 19, 2022 Gainers Talis Biomedical (NASDAQ:TLIS) shares moved upwards by 10.6% to $0.94 during Tuesday's after-market session. The company's market cap stands at $25.0 million. Via Benzinga ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results July 14, 2022 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 01, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates June 13, 2022 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 01, 2022 From ImmunoGen, Inc. Via Business Wire Immunogen's Return On Capital Employed Overview May 31, 2022 According to Benzinga Pro data, during Q1, Immunogen (NASDAQ:IMGN) posted sales of $38.08 million. Earnings were up 35.05%, but Immunogen still reported an overall loss of $24.14 million. Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session May 27, 2022 Via Benzinga ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO May 26, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences May 25, 2022 From ImmunoGen, Inc. Via Business Wire What's Going On With ImmunoGen Shares Today? May 23, 2022 ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review. Via Benzinga ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review May 23, 2022 From ImmunoGen Via Business Wire Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression May 18, 2022 Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30... Via FinancialNewsMedia Topics Death Exposures Death ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference May 10, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results May 06, 2022 From ImmunoGen, Inc. Via Business Wire Immunogen Earnings Preview May 05, 2022 Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will... Via Benzinga ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 02, 2022 From ImmunoGen, Inc. Via Business Wire Earnings Scheduled For May 6, 2022 May 06, 2022 Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. Via Benzinga The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More May 02, 2022 Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... Via Benzinga Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating April 25, 2022 Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer... Via FinancialNewsMedia Topics Intellectual Property Exposures Intellectual Property < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.